OpenAlex
PricingAboutJobs
Log inGet started
Work

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant: A cost-effectiveness analysis updated with 5-year follow-up data from the pivotal trial.

HTML

Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
DOI: 10.1200/jco.2016.34.7_suppl.19
Authors: Christopher Parker, Gemma Kay, Esprit Ma, Beth Woods, James Eaton, Peter Sajosi, Andreas Engstrom, Ross Selby, Eugene Benson, Jeremy Teasell, Akshara Richhariya, Andrew Briggs, Vijayveer Bonthapally
Institutions: Tufts Medical Center, University of York, Takeda Oncology (United States), Takeda (United Kingdom), Seagen (United States), University of Glasgow
Language: English

Topic: Health Systems, Economic Evaluations, Quality of Life
Subfield: Economics and Econometrics
Field: Economics, Econometrics and Finance
Domain: Social Sciences
Keywords: brentuximab vedotin, relapsed/refractory Hodgkin lymphoma, autologous stem cell transplantation, cost-effectiveness, incremental cost-effectiveness ratio, quality-adjusted life years, partitioned survival model, post-progression survival
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2464239697
Cites:
Cited by: 1
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security